Final week we talked about biotech penny stocks with upcoming catalysts. That article bought lots of attention and for glaring reasons. As I explained, few industries will host firms that will repeat you once they’ve got news coming. Biotech is one among those industries, and it makes for thrilling market situations. You’ve got the “dangle the rumor, promote the news” pattern to navigate.
PennyStocks.com – PennyStocks
Then there’s the market surprise where firms sing results a long way surpassing what Wall Boulevard within the starting up opinion. One thing to take into story is that there are such diverse diversified steps occupied with taking a biotech company from pre-medical to commercial phases. Each portion provides a milestone different.
Biotech stocks are thrilling to learn about, especially round these skill milestone events. These are all issues to rob in thoughts, whether it’s an industry presentation, contemporary seek for knowledge, or something else.
The Stock Market This Week
We’ve got several issues to rob in thoughts within the stock market this week. It’s the final week of September, that manner an discontinue to one among the most now not easy months within the stock marketplace for 2021. It’s also the discontinue of the Third quarter. Over the final 12 months, firms beget reported real dates and tall intervals.
“By the discontinue of Q3” is one among those tall timeframes. So this day, we’re going to beget a examine 10 high penny stocks presumed to beget something to take glimpse of this week. Will these events change into bullish or bearish catalysts? While you’re making an attempt for penny stocks to dangle, I’ll leave that final decision as a lot as you. On the very least, you’re armed with knowledge heading into the discontinue of September and the discontinue of Q3.
Penny Stocks To Bear This Week
|1. Zynerba Prescribed capsules Inc. (NASDAQ:ZYNE)||September 27, 2021|
|2. Verastem Oncology (NASDAQ:VSTM)||September 27, 2021|
|3. Lineage Cell Therapeutics, Inc. (NYSE:LCTX)||September 27, 2021
September 30, 2021
|4. Rigel Prescribed capsules Inc. (NASDAQ:RIGL)||September 28, 2021|
|5. Asensus Surgical Inc. (NYSE:ASXC)||September 28, 2021|
|6. 9 Meters Biopharma Inc. (NASDAQ:NMTR)||September 28, 2021|
|7. Arbutus Biopharma Company (NASDAQ:ABUS)||September 30, 2021|
|8. CTI BioPharma Corp. (NASDAQ:CTIC)||Q3 2021|
|9. ASLAN Prescribed capsules Restricted (NASDAQ:ASLN)||Q3 2021|
|10. Precigen Inc. (NASDAQ:PGEN)||October 1, 2021|
Penny Stocks To Bear On September 27:
Zynerba Prescribed capsules Inc.
Zynerba is one among the corporate’s we talked about final week on a listing of penny stocks analysts divulge to dangle apt now. H.C. Wainwright analyst Oren Livnat reiterated the firm’s To find rating on ZYNE stock and a label target of $9. Other than that, there are other more scientific issues to place in thoughts when having a beget a examine Zynerba. The company makes a speciality of transdermal therapies for uncommon and near-uncommon disorders.
It made several shows this month on its ZYN002 platform, trademarked as Zygel. This product is a transdermal gel administered to formative years with developmental and epileptic encephalopathy. Present results of ongoing reports beget demonstrated how Zygel can income sufferers even correct by longer-interval of time time frames. Sufferers with Autism Spectrum Disorder who done a 38-week treatment showed “statistically important improvements” in comparison to baselines within the seek for.
What To Bear With ZYNE Stock This Week
As you’ll reach to win, the Cantor Global Healthcare Conference will be a level of level of curiosity for many firms this week. The conference goes from September 27 – September 30. On September 27th, Zynerba’s CEO Armando Anido begins his presentation at 11: 20 AM ET. Resolve this in thoughts if ZYNE is for your listing of penny stocks this week.
Verastem Oncology Inc.
Yet some other one among the agencies that we’ve assuredly talked about this month is Verastem. No longer simplest turn out to be once it highlighted for bullish analyst sentiment, nevertheless it turn out to be once also spotlighted for a biotech match final week. Verastem introduced that seek for knowledge in a aggregate of its VS-6766 and defactinib demonstrated skill in treating ovarian most cancers. The company acknowledged that the median progression-free survival across all sufferers turn out to be once 23 months.
Moreover to these results, Verastem also introduced a medical collaboration settlement with Amgen (NASDAQ:AMGN), evaluating a aggregate of VS-6766 with Amgen’s sotorasib, trademarked as LUMAKRAS, in sufferers with non-minute cell lung most cancers. This trial is anticipated to commence by the discontinue of the year. So that will presumably well perchance be something to rob in thoughts later on correct by Q4.
What To Bear With VSTM Stock This Week
Similar to Zynerba, VSTM stock will be in level of curiosity this week as administration provides at the Cantor Conference. September 27 would possibly perchance presumably also be the date to rob in thoughts right here. The company begins its presentation at 4 PM ET.
Lineage Cell Therapeutics
Similar to Rigel, the final year turn out to be once a pivotal one for enhance in Lineage Cell Therapeutics. Final September, shares of LCTX stock traded under $1. Heading into this week, they’re firmly trading above $2. Right here’s what’s gone on with Lineage and why this week would possibly perchance presumably well perchance well be crucial for the corporate.
Lineage makes a speciality of allogeneic cell therapies for issues love dry age-related macular degeneration (AMD). Its OpRegen treatment is being studied for this indication in ongoing portion trials, having already demonstrated improvements in seek for sufferers. The company will most likely be increasing OPC1 for subacute spinal cord injuries and VAC2 to tackle non-minute cell lung most cancers.
What To Bear With LCTX Stock This Week
Lineage is going by double-responsibility this week. The principle date to markdown is September 27. Company CEO Brian Culley begins presenting at a fireside chat correct by the Cantor Healthcare conference at 4 PM ET. Later this week, updated interval in-between results from its Segment 1/2a seek for of OpRegen® will be featured in a podium presentation at the 54th Annual Scientific Meeting of the Retina Society. This presentation begins on September 30 at 9: 52 AM EDT.
Penny Stocks To Bear On September 28:
Rigel Prescribed capsules Inc.
Despite September being a mixed month for the corporate’s shares, Rigel has experienced important enhance over the final year. This time in 2020, shares of RIGL stock had been trading a minute higher than $2. Heading into this week, the stock is trading marginally lower than $4.
The biotech company develops minute molecule medication for treating hematologic disorders, most cancers, and uncommon immune diseases. The company’s first FDA-permitted product, TAVALISSE (fostamatinib disodium hexahydrate), is used in treating power immune thrombocytopenia. Fostamatinib will most likely be being studied in numerous medical trials for treating anemia to boot to COVID-19. The latter has helped sing just some of the “hype” ingredient into the combo this year, due to increased attention on COVID stocks.
Earlier this month, the consequences from a Segment 2 trial evaluating fostamatinib for hospitalized COVID sufferers had been published in Scientific Infectious Ailments. Recordsdata showed that treatment with fostamatinib turn out to be once well tolerated and related to clinically important enchancment in outcomes of hospitalized sufferers.
What To Bear With RIGL Stock This Week
All over again, industry conferences are the level of curiosity. This week Rigel’s Raul Rodriguez provides an organization overview at Cantors Global Healthcare Conference. Divulge RIGL stock is for your listing, markdown September 28 at 4: 40 PM ET. Rodriguez begins his presentation within the intervening time.
Asensus Surgical Inc.
Shares of ASXC stock started the year sturdy. For the rationale that starting up of April, the general pattern has been largely sideways. There turn out to be once a immediate spike in June, nevertheless issues beget subsided. With out a doubt one of many issues that continue retaining investors’ pursuits is the corporate’s medical instrument platform. Asensus’ Wise Surgical Unit (ISU) turn out to be once designed to amplify surgeon retain watch over and streamline surgical treatment experiences and outcomes. The company’s utilization of machine vision and augmented intelligence has introduced a contemporary layer of workmanship into the working room.
Earlier this month, its ISU instrument bought FDA 510(k) clearance to amplify machine vision capabilities. Right here is used with the corporate’s Senhance Surgical Plan enabling digital laparoscopy.
What To Bear With ASXC Stock This Week
This week Asensus continues its industry presentation circuit. The Third and final presentation will be at, you guessed it, the Cantor Healthcare Conference. Company CEO Anthony Fernando and CFO Shameze Rampertab commence their presentation at 1: 20 PM ET on September 28.
9 Meters Biopharma Inc.
The previous couple of weeks for 9 Meters Biopharma had been sturdy. Shares of NMTR stock moved up from round $1 in mid-August to over $1.30 final week. Helping enhance sentiment turn out to be once a combination of more a lot earnings results and contemporary offers contributing to advancing the corporate’s treatment pipeline.
Particularly, 9 Meters introduced a collaboration with the European Biomedical Analysis Institute of Salerno, Italy (EBRIS). This turn out to be once to hunt for the corporate’s larazotide to tackle multisystem inflammatory syndrome in formative years (MIS-C). Larazotide will most likely be in Segment 3 medical pattern for adults with celiac illness. EBRIS plans to starting up out a Segment 2a seek for in MIS-C in Q4 2021.
Yet some other side of this story bringing hobby to NMTR stock is analyst and insider sentiment. In September, Director Designate Sirgo and CFO Edward Sitar bought a total of 88,529 between sensible costs of $1.22 and $1.36. Sirgo accounted for the extensive majority of that, with over 73,000 shares bought at an sensible label of $1.36, bringing his without extend controlled situation to over 1.1 million shares. Analysts at BMO Capital are also bullish apt now. The firm has an Outperform rating on the stock and a $5 label target.
What To Bear This Week With NMTR Stock
Similar to Asensus, 9 Meters is buttoning up a circuit of shows this week. CEO John Temperato provides at Cantor’s Healthcare Conference on September 28, starting up at 4: 40 PM ET.
Penny Stocks To Bear On September 30:
Arbutus Biopharma Company
Shares of Arbutus had been red sizzling over the last few months. Beginning in August, ABUS stock started its climb, profiting from more a lot gross sales leads to the second quarter to boot to an upbeat outlook from administration pertaining to Arbutus’ treatment pipeline.
William Collier, President and Chief Executive Officer of Arbutus, explained, “We had a productive second quarter, particularly in advancing our efforts to situation AB-729 as a skill cornerstone therapy in future HBV aggregate regimens. Our honest now not too long within the past introduced proof-of-opinion medical collaborations with Vaccitech plc and Antios Therapeutics, Inc. to place in thoughts AB-729 with other agents reflects this blueprint, as does our planned Segment 2a medical trial to place in thoughts AB-729 alongside with Peg-IFNα-2a.”
Loads of the level of curiosity has been on Arbutus versus Moderna, believe it or now not. The 2 conflicted over Arbutus’s lipid formulations for nucleic acid supply. Earlier this month, the European Patent Instruct of enterprise acknowledged that its 069 patent related to lipid formulations turn out to be once “Inventive” (reputable). It turn out to be once in settlement with the US Patent and Trademark Instruct of enterprise, which granted a glimpse of allowance this month. Moderna is shifting ahead with an allure blueprint for a listening to subsequent month. However, if Arbutus is correct, it would possibly perchance well per chance presumably well launch the doors for eligibility to salvage royalties from Moderna’s COVID-19 vaccine gross sales.
What To Bear With ABUS Stock This Week
The company provides at the Cantor Global Healthcare Conference that many others on this listing of penny stocks will be in attendance this week. CEO William Collier will give the presentation starting up at 8: 40 AM ET. So if ABUS stock is for your listing apt now, retain September 30th in thoughts.
Penny Stocks to Bear At The Stay of Q3:
CTI BioPharma Corp.
CTI Biopharma kicks off the portion of this listing of penny stocks that haven’t given explicit dates. However, since right here is the final week of the Third quarter, the countdown has begun for firms love CTI to sing on their previously introduced plans.
The company has focused its efforts on advancing its centered treatment platform geared in direction of blood-related cancers. It targets sufferers with myelofibrosis and severe COVID-19 in response to the 2020/2021 pandemic. Its contemporary pipeline treatment involves pacritinib for treating myelofibrosis, which has a Novel Drug Utility under evaluation by the FDA. There’s a Prescription Drug User Price Act date of November 30th. So as the fourth quarter begins, that will be a really crucial date to rob in thoughts. Interested by that the corporate has already started commercialization actions, CTI appears to be like optimistic referring to the FDA’s skill decision. However, as the announcing goes, they gained’t know till they know.
What To Bear With CTIC Stock This Week
This week would possibly perchance presumably well perchance well be all about COVID 19 for CTI Biopharma. In its second-quarter financial results and change change, administration explained that they count on to sing interval in-between diagnosis from a Segment 3 PRE-VENT trial in hospitalized sufferers with severe COVID-19 this quarter.
ASLAN Prescribed capsules
Yet some other one among the “Q3 penny stocks to learn about” is ASLAN Prescribed capsules. The company specializes in treatments for immune diseases. It’s currently evaluating several treatment candidates. Its ASLAN004 targets atopic dermatitis, and its ASLAN003 specializes in autoimmune illness.
What To Bear With ASLN Stock This Week
In June, the corporate done the recruitment of 27 sufferers into the expansion cohort of the double-blind placebo-controlled multiple ascending dose seek for. Topline knowledge is anticipated at the discontinue of this quarter, in step with the corporate’s August sixth change. One thing to keep in mind is that earlier this year, knowledge from a single ascending dose seek for demonstrated that ASLAN004 has a favorable tolerability profile and skill as a clear treatment draw for atopic dermatitis. With the multiple ascending dose seek for yield a an identical response?
Penny Stocks To Bear On October 1:
On the higher discontinue of the penny stock differ, Precigen will be on the listing of penny stocks to learn about this week. However you’ll beget to wait just a few days for its skill catalyst date. One thing to know referring to the corporate is that it’s worked diligently on advancing its gene and cell therapies with this year as a really crucial one for the corporate.
Administration elaborated on this in its most unusual quarterly change change. Helen Sabzevari, Ph.D., President, and CEO of Precigen, acknowledged, “We glance 2021 as a pivotal year for the UltraCAR-T, ActoBiotics, and AdenoVerse platforms with important contemporary medical knowledge on our most evolved therapeutic candidates from these core therapeutic platforms.”
What To Bear With PGEN Stock This Week
ActoBiotics is mostly is named AG019 ActoBiotics, will be the level of curiosity this week. Extra knowledge from its AG019 Segment 1b/2a medical trial will be provided on October 1 at noon CET as an oral presentation at the European Association for the Watch of Diabetes Meeting. The abstract entitled, “AG019 ActoBiotics as monotherapy or in association with teplizumab in most unusual-onset type 1 diabetes turn out to be once protected and demonstrated encouraging metabolic and immunological effects” will be provided by Chantal Mathieu, MD, Ph.D., Professor of Remedy at the Katholieke Universiteit Leuven, Belgium. Moreover, a medical trial assessing the efficacy of prolonged treatment of oral AG019 will most likely be planned.
One thing to command is that clear topline knowledge from the AG019 Segment 1b/2a medical trial had been reported earlier this year at the Federation of Scientific Immunology Societies Meeting. The principle endpoints of safety and tolerability for the Segment 1b AG019 monotherapy and the Segment 2a AG019 aggregate therapy had been met. No severe adverse events had been reported both.
Penny Stocks To Bear This Week
There are lots of biotech penny stocks to learn about this week, including those talked about in this text. Resolve in thoughts that apt since the corporate has previously introduced a date, that doesn’t mean knowledge released will be clear (or unfavorable, for that topic). However, what it does mean is that there would possibly perchance presumably well perchance well be contemporary knowledge to ingredient in. With that will presumably well reach lots of volatility and, if favorable, alternatives to capitalize. Will that be the case this week?